- Home
- OUT vs RYTM Comparison
OUT vs RYTM Comparison
Compare OUT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OUT
- RYTM
- Stock Information
- Founded
- OUT 2013
- RYTM 2008
- Country
- OUT United States
- RYTM United States
- Employees
- OUT N/A
- RYTM N/A
- Industry
- OUT Real Estate Investment Trusts
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- OUT Real Estate
- RYTM Health Care
- Exchange
- OUT Nasdaq
- RYTM Nasdaq
- Market Cap
- OUT 2.9B
- RYTM 3.1B
- IPO Year
- OUT N/A
- RYTM 2017
- Fundamental
- Price
- OUT $18.94
- RYTM $54.54
- Analyst Decision
- OUT Hold
- RYTM Strong Buy
- Analyst Count
- OUT 6
- RYTM 10
- Target Price
- OUT $19.00
- RYTM $66.90
- AVG Volume (30 Days)
- OUT 1.6M
- RYTM 580.8K
- Earning Date
- OUT 02-19-2025
- RYTM 02-20-2025
- Dividend Yield
- OUT 4.76%
- RYTM N/A
- EPS Growth
- OUT N/A
- RYTM N/A
- EPS
- OUT 1.41
- RYTM N/A
- Revenue
- OUT $1,838,900,000.00
- RYTM $112,530,000.00
- Revenue This Year
- OUT N/A
- RYTM $63.77
- Revenue Next Year
- OUT $1.95
- RYTM $44.91
- P/E Ratio
- OUT $13.40
- RYTM N/A
- Revenue Growth
- OUT 1.37
- RYTM 81.55
- 52 Week Low
- OUT $12.57
- RYTM $35.17
- 52 Week High
- OUT $19.98
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- OUT 59.01
- RYTM 43.02
- Support Level
- OUT $17.17
- RYTM $52.71
- Resistance Level
- OUT $18.29
- RYTM $60.12
- Average True Range (ATR)
- OUT 0.48
- RYTM 2.13
- MACD
- OUT 0.08
- RYTM -0.36
- Stochastic Oscillator
- OUT 83.48
- RYTM 23.48
About OUT OUTFRONT Media Inc.
Outfront Media Inc is a real estate investment trust involved in the ownership of advertising space on its portfolio of billboards and transit displays. The Company generates revenue in the form of rental income by allowing other companies to advertise on its properties and structures under short-term contracts. Outfront Media segments its operations into the United States and International units. Although it also owns assets in Canada and Latin America, the company derives the vast majority of its revenue from billboard advertising agreements in the U.S. Roughly half of the U.S. division's revenue comes from its displays in the New York City and Los Angeles markets. Outfront Media's major customers include entities within the retail, television, healthcare, and entertainment industries.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.